MASLD

42 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Phosphatidylethanol Reveals Substantial Underestimation of Alcohol Intake in Patients at Risk of Steatotic Liver Disease

A large prospective cohort shows phosphatidylethanol (PEth) correlates with self-reported alcohol intake but identifies frequent under-reporting; adding PEth to diagnostic pathways could improve subclassification of steatotic liver disease

Section: GastroenterologyNov 9, 2025

Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts

A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.

MASLD

Latest news

Phosphatidylethanol Reveals Substantial Underestimation of Alcohol Intake in Patients at Risk of Steatotic Liver Disease

Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

Standardizing Liver Biopsy Interpretation in MASH Trials: Key Consensus Statements from the International MASLD Pathology Group

Comparative Risks of MASLD and MetALD: Insights from a Comprehensive Meta-Analysis on Hepatic and Extrahepatic Outcomes

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients

Intermittent Calorie Restriction: A Promising Dietary Strategy for Metabolic Dysfunction-Associated Steatotic Liver Disease

Empowering Community Liver Health: Insights from the LOCATE-NAFLD Trial on Nurse-Led MASLD Screening

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial

Waist Size Proves Key to Assessing Liver Health

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort